Researchers conducted a systematic review of studies assessing the cost-effectiveness or cost-utility of adjuvant immunotherapy for treating various types of cancer.

Cost-effectiveness considerations are highlighted by Dr Abou-Alfa. The video discussion revolves around the critical elements of managing hepatocellular carcinoma (HCC) and the complexities involved ...

As Clostridium difficile creates a significant economic and morbidity burden for hospitals, researchers with Cleveland Clinic and the University of Texas School of Public Health in Houston sought to ...

This systematic review found that studies of case management interventions have adequate quality and, in many cases, show cost-effective or even cost-saving results. Results: A total of 29 studies ...

Prospective evaluation of the breast microbiome and tumor microenvironment-related biomarkers of response to neoadjuvant systemic therapy in triple negative breast cancer. Phase III study to evaluate ...

Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...

A new methodological framework for assessing agreement between cost-effectiveness endpoints generated using alternative sources of data on treatment costs and effects for trial-based economic ...

Patient-reported pain and other symptoms as prognostic factors for overall survival (OS) in a phase III clinical trial of patients with advanced breast cancer. This is an ASCO Meeting Abstract from ...

Objective To assess the costs and cost-effectiveness of percutaneous transforaminal endoscopic discectomy (PTED) compared with open microdiscectomy among patients with sciatica. Methods This economic ...